Increasing Prevalence Of Infectious Diseases Is Driving The Growth Of The Positron Emission Tomography (PET) Radiotracer Market: A Key Catalyst Accelerating Positron Emission Tomography (PET) Radiotracer Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Positron Emission Tomography (PET) Radiotracer Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of the positron emission tomography (pet) radiotracer has witnessed a significant increase in recent times. It's projected to escalate from a value of $2.35 billion in 2024 to around $2.54 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.3%. The growth during the historical span can be associated with the escalating occurrence of infectious diseases, greater awareness and accessibility, the advent of new radiotracers, an increasing incidence of cancer, and a heightened emphasis on preventive healthcare.

Positron Emission Tomography (PET) Radiotracer Market Size Forecast: What's the Projected Valuation by 2029?
In the next few years, the market size for positron emission tomography (pet) radiotracers is projected to experience significant growth, reaching $3.61 billion by 2029 with a compound annual growth rate (CAGR) of 9.2%. This growth throughout the forecast period is associated with the broadening of applications, regulatory approvals, growth in budding markets, an increasing elderly population, and the increasing implementation of PET radio scanners. Prominent trends within this forecast timeframe consist of the evolution of micro-pet technology, integration with wearable technologies, expansion of theranostics, nano-radiotracers, and blockchain application for data protection.

View the full report here:
https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-radiotracer-global-market-report

What Are the Drivers Transforming the Positron Emission Tomography (PET) Radiotracer Market?
There is an expectation for the positron emission tomography (PET) radiotracer market to amplify its growth due to the escalating instances of infectious diseases. These diseases arise from pathogenic microorganisms like bacteria, viruses, fungi, or parasites. Factors such as climate transformation, urban proliferation, global integration, resistance to antibiotics, and human behavioral shifts contribute to the spread of these pathogens and thus increase disease prevalence. PET radiotracers contribute to the management of these ailments by portraying metabolic activity and inflammation, which facilitates the determination of infection, evaluating the response to treatment, and distinguishing between infectious and non-infectious scenarios for better patient prognosis. For instance, a report issued in February 2024 by the UK Health Security Agency, a governmental body in the UK, illustrated a 10.7% surge in tuberculosis (TB) cases in England during 2023, recording 4,850 cases compared to 4,380 in the prior year, 2022. Thus, this growing prevalence of infectious diseases propels the growth of the positron emission tomography (PET) radiotracer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp

Which Emerging Trends Are Transforming the Positron Emission Tomography (PET) Radiotracer Market in 2025?
Leading organizations in the positron emission tomography (PET) radiotracer sector are concentrating their efforts on creating cutting-edge diagnostic tools, one being PET imaging agents. These aim to elevate success rates in cancer detection and better patient outcomes overall. PET imaging agents represent radioactive substances that assist in visualizing and quantifying bodily processes during PET scans. For example, IsoLogic Innovative Radiopharmaceuticals, a radiopharmaceutical firm from Canada, introduced Illuccix - a prostate cancer imaging agent, in the country in March 2023. Also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), this product greatly helps physicians to recognize metastatic diseases and contributes to effective patient management. It is recommended for use in patients suspected of metastasis and are in line for initial definitive therapy, and also patients who show signs of recurrence via elevated serum prostate-specific antigen (PSA) levels.

Which Segments in the Positron Emission Tomography (PET) Radiotracer Market Offer the Most Profit Potential?
The positron emission tomography (pet) radiotracer market covered in this report is segmented -

1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)
2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19152&type=smp

Which Firms Dominate the Positron Emission Tomography (PET) Radiotracer Market by Market Share and Revenue in 2025?
Major companies operating in the positron emission tomography (PET) radiotracer marker are Cardinal Health Inc., AstraZeneca PLC, Eli Lilly and Company, Siemens Healthineers AG, GE Healthcare Technologies Inc., Philips Healthcare, Bracco Imaging S.p.A., Neusoft Medical Systems Co Ltd., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences (SOFIE), Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., RefleXion Medical Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., IXICO PLC, ImaginAb Inc., Radiomedix Inc.

Which Regions Offer the Highest Growth Potential in the Positron Emission Tomography (PET) Radiotracer Market?
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) radiotracer marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19152

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.